SCHEMBL291089

SCHEMBL291089

O=[C]Cc1ccc(O)c([N+](=O)[O-])c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.54
MAPK1 P28482 2/20 0.53
ALDH1A1 P00352 2/20 0.53
TP53 P04637 1/20 0.53
HPGD P15428 1/20 0.53
TSHR P16473 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
GPR35 Q9HC97 1/20 0.53
ALDH5A1 P51649 1/20 0.53
ABAT P80404 1/20 0.53
MAPT P10636 4/20 0.52
NPSR1 Q6W5P4 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.51
ALOX15 P16050 1/20 0.51
HSD17B10 Q99714 1/20 0.51
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
DBH P09172 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11679213 0.85 POLB (0.52) POLBMAPK1ALDH1A1TP53HPGD
SCHEMBL6947524 0.84 TSHR (0.47) POLBMAPK1ALDH1A1HPGDTSHR
SCHEMBL11002820 0.82 MAPK1 (0.60) POLBMAPK1ALDH1A1TP53HPGD
SCHEMBL69585 0.82 SNCA (0.62) POLBMAPK1ALDH1A1TP53HPGD
SCHEMBL30477507 0.82 SNCA (0.62) POLBMAPK1ALDH1A1TP53HPGD
SCHEMBL6950412 0.81 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2MAPTNPSR1CA1
SCHEMBL1736272 0.80 POLB (0.62) POLBMAPK1ALDH1A1TP53HPGD
SCHEMBL1467557 0.79 MAPK1 (0.61) POLBMAPK1ALDH1A1TP53HPGD
SCHEMBL1025776 0.79 POLB (0.56) POLBMAPK1ALDH1A1TP53HPGD
SCHEMBL3529585 0.79 POLB (0.56) POLBMAPK1ALDH1A1TP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759489-B2 Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-06-24 US claimed
US-20120157663-A1 ANTIBODY IDENTIFYING AN ANTIGEN-BOUND ANTIBODY AND AN ANTIGEN-UNBOUND ANTIBODY, AND METHOD FOR PREPARING THE SAME Tokyo University Science 2012-06-21 US claimed
US-6503714-B1 Contacting the sample with a probe under conditions in which said substance if present binds directly or indirectly to the probe, a plurality of nucleobases covalently attached to at least one strand of backbone comprising a plurality of atoms ROCHE DIAGNOSTICS GMBH (DE) 2003-01-07 US claimed
US-6214549-B1 CONTACTING SAMPLE WITH PROBE COMPRISING STEM AND BRANCH SUCH THAT SUBSTANCE IF PRESENT BINDS DIRECTLY OR INDIRECTLY TO PROBE; MIXING BINDING PRODUCT WITH CONJUGATE; REMOVING UNBOUND CONJUGATE FROM MIXTURE; DETERMINING PRESENCE OF CONJUGATE ROCHE DIAGNOSTICS GMBH (DE) 2001-04-10 US claimed
WO-1996029088-A1 NOVEL PIPERAZINE DERIVATIVES AS TYPE IL-1 RECEPTOR ANTAGONISTS AFFYMAX TECHNOLOGIES N.V. (AN) 1996-09-26 WO claimed
US-12018291-B2 Compositions and methods for antigen targeting to CD180 UNIVERSITY OF WASHINGTON (US) 2024-06-25 US disclosed
US-20240197867-A1 NEURAL CONTROL OF ADAPTIVE IMMUNITY THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2024-06-20 US disclosed
WO-2024124052-A1 IMMUNE ADJUVANTS FOR POLYSACCHARIDE VACCINES THOMAS JEFFERSON UNIVERSITY (US) 2024-06-13 WO disclosed
EP-4380616-A2 METHOD AND MEANS FOR ENHANCING THERAPEUTIC ANTIBODIES Vaccinvent GmbH (DE) 2024-06-12 EP disclosed
US-12006364-B2 Anti-CD100 antibodies and methods for using the same VACCINEX, INC. (US) 2024-06-11 US disclosed
US-11999772-B2 Antibodies comprising a polypeptide inserted in framework 3 region UCB Biopharma SRL (BE) 2024-06-04 US disclosed
US-20240150494-A1 GLYCOFORM SPECIFIC NANOBODIES AND METHODS OF USE THE ROCKEFELLER UNIVERSITY 2024-05-09 US disclosed
WO-1986006490-A1 METHOD FOR AUGMENTING IMMUNE RESPONSE NEW YORK UNIVERSITY (US) 1986-11-06 WO disclosed
EP-0194276-A1 PRODUCTION OF CHIMERIC ANTIBODIES. CELLTECH LTD (GB) 1986-09-17 EP disclosed
WO-1986001533-A1 PRODUCTION OF CHIMERIC ANTIBODIES CELLTECH LIMITED (GB) 1986-03-13 WO disclosed
EP-0122080-A1 A process for the production of a protein CELLTECH LIMITED (GB) 1984-10-17 EP disclosed
EP-0120694-A2 Processes for the production of multichain polypeptides or proteins CELLTECH LIMITED (GB) 1984-10-03 EP disclosed
WO-1984003711-A1 A PROCESS FOR THE PRODUCTION OF A PROTEIN CELLTECH LTD (GB) 1984-09-27 WO disclosed
WO-1984003712-A2 MULTICHAIN POLYPEPTIDES OR PROTEINS AND PROCESSES FOR THEIR PRODUCTION CELLTECH LTD (GB) 1984-09-27 WO disclosed
EP-0106615-A2 Assay for the free portion of substances in biological fluids AMERSHAM INTERNATIONAL plc (GB) 1984-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240197867-A1 NEURAL CONTROL OF ADAPTIVE IMMUNITY TRPV1, TRPA1, TRPV2 POLB 4841/4885MAPK1 1414/4885ALDH1A1 3315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.